- In February 2023, Rhythm Pharmaceuticals, Inc., a global biopharmaceutical company dedicated to transforming the lives of patients and families affected by hyperphagia and severe obesity due to rare melanocortin-4 receptor (MC4R) pathway diseases, announced that its Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V., has acquired Xinvento B.V. Xinvento is a biotech company based in the Netherlands, focused on developing treatments for congenital hyperinsulinism (CHI), a rare genetic disorder where excess insulin secretion leads to hypoglycemia, potentially resulting in severe health complications such as seizures, coma, permanent brain damage, and death
- In September 2022, Novo Nordisk and Microsoft formed a strategic partnership to combine Microsoft’s AI, cloud, and computational services with Novo Nordisk’s expertise in drug discovery, development, and data science. This collaboration aims to leverage AI technology and foundational scientific models to accelerate Novo Nordisk’s research and development efforts
- In April 2022, Xinvento, a biotech company focused on improving treatments for Congenital Hyperinsulinism (CHI), announced the completion of a seed funding round. Founded by CEO Claudine van der Sande, whose son has CHI, the funding will support Xinvento in designing and testing proprietary molecules in preclinical models to identify potential drug candidates
- In August 2021, Eiger BioPharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for avexitide, a treatment for congenital hyperinsulinism (HI). This designation helped the company expedite the drug's development and review process.
- In April 2021, AmideBio, LLC, announced that its glucagon analog (ABG-023) received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism. This strategy enabled the company to expand its product portfolio and increase its customer base.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Diffuse Hyperinsulinism and Focal Hyperinsulinism), Drug Type (Diiazoxide, Octreotide, and Nifedipine), Gender (Males and Females), Route of Administration (Intravenous, Oral, and Parenteral), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031
.
The Global Congenital Hyperinsulinism Market size was valued at USD 145.56 USD Billion in 2023.
The Global Congenital Hyperinsulinism Market is projected to grow at a CAGR of 12.65% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
